International Journal of Clinical Research

This article systematically evaluated the practical application effect of the standardized antiemetic protocol in the daytime chemotherapy center for tumors. The study took 1,234 patients who received daytime chemotherapy at Deyang People's Hospital from May 2024 to May 2025 as the subjects and randomly grouped them to compare the effects of triple therapy (NK1 receptor antagonist, 5-HT3 receptor antagonist and dexamethasone), dual therapy and monotherapy. The results showed that the complete remission rate of the triple therapy reached 82.3%, significantly higher than that of the other two groups, especially with a clear advantage in highly emetic chemotherapy regimens. Research has confirmed that the combination of multiple mechanisms not only enhances the antiemetic efficacy but also maintains good safety, suggesting that antiemetic treatment should shift towards a "patient-oriented" model. By optimizing strategies through individualized assessment, it provides an evidence-based basis for the construction of standardized daytime chemotherapy antiemetic regimens.

Daytime chemotherapy for tumors; Standardized antiemetic regimens; Triple therapy; Chemotherapy-associated nausea and vomiting (CINV); Individualized treatment